Prostate Cancer - Results from #1920

Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1/2 Study. November 6, 2023

Real-world treatment patterns and overall survival among men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) in the US Medicare population. November 6, 2023

Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers. November 6, 2023

Heterogeneous genetic architectures and evolutionary genomics of prostate cancer in Sub-Saharan Africa. November 6, 2023

Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591. November 6, 2023

MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis. November 6, 2023

Impact of sequencing of androgen receptor-signaling inhibition and radiotherapy in prostate cancer: importance of homologous recombination disruption. November 6, 2023

Zone-specific computer-aided diagnosis system aimed at characterizing ISUP ≥ 2 prostate cancers on multiparametric magnetic resonance images: evaluation in a cohort of patients on active surveillance. November 6, 2023

Mortality Risk for Docetaxel-Treated, High-Grade Prostate Cancer With Low PSA Levels: A Meta-Analysis. November 3, 2023

Statin use and outcomes of oncological treatment for castration-resistant prostate cancer. November 3, 2023

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer. November 3, 2023

Preclinical evaluation of [58mCo]Co-DOTA-PSMA-617 for Auger electron therapy of prostate cancer. November 3, 2023

The 29th Annual Prostate Cancer Foundation Scientific Retreat Report. November 3, 2023

Targeting MALAT1 Augments Sensitivity to PARP Inhibition by Impairing Homologous Recombination in Prostate Cancer. November 3, 2023

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer. November 3, 2023

Androgen blockade primes NLRP3 in macrophages to induce tumor phagocytosis. November 3, 2023

Clinically relevant humanized mouse models of metastatic prostate cancer to evaluate cancer therapies. November 3, 2023

Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer. November 3, 2023

5-hydroxymethylcytosine sequencing in plasma cell-free DNA identifies unique epigenomic features in prostate cancer patients resistant to androgen deprivation therapy. November 3, 2023

Concordance and Clinical Significance of Genomic Alterations in Progressive Tumor Tissue and Matched Circulating Tumor DNA in Aggressive-Variant Prostate Cancer. November 3, 2023

Page 97 of 1439